PRX-303

N/A

Report date: 2023/03/12 14:49:30
NME

Base Information

Drug NamePRX-303
Drug Alias NamePRX-303
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionSynuclein alpha degraders
TargetsSynuclein alpha
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPrazer Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesPrazer Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A